Viz.ai Launches New Strategic Alliance to Accelerate Timely Diagnosis and Deliver AI-Powered Precision Care for Patients with Cancer
For patients with cancer, every day matters. Yet too often, diagnosis and treatment are delayed by fragmented systems, manual reviews, and complex care journeys. These inefficiencies can lead to missed diagnoses, delayed access to life-extending therapies, and worse outcomes. This collaboration aims to address that, using AI to help ensure patients are surfaced and treated earlier, with care that's timely, coordinated, and personalized.
'We are excited to be partnering with Novartis, an innovative medicines company and a leader in oncology, to accelerate access to timely, guideline-based care for patients facing prostate and breast cancer,' said Chris Mansi, MD, CEO and co-founder of Viz.ai. 'This collaboration is part of our broader strategic expansion into oncology, furthering Viz.ai's mission to fundamentally transform healthcare through intelligent care coordination.'
As part of the collaboration Viz.ai will be developing two new AI-powered solutions:
Viz Prostate Cancer, designed to streamline the identification of eligible patients for guideline-based treatment and support timely referrals to an appropriate specialist. Only one in four patients receives guideline-recommended therapy for prostate cancer, and thousands of patients with advanced disease who are eligible for potential life-extending treatments are never identified. 1,2
Viz Breast Cancer, designed to support breast oncologists by automating patient review, aggregating risk-relevant data, surfacing therapeutic guidelines, and facilitating coordination among multidisciplinary care teams. Breast cancer is the most widely diagnosed cancer in the United States, with patient care journeys that are complex, time-consuming, and often fragmented. 3
'Earlier diagnosis and interventions can positively impact patient outcomes. At Novartis, we lead the industry in fostering bold partnerships and initiatives that support early screening and diagnosis; we are also leveraging innovative, data-driven technologies to help connect patients with appropriate care as quickly as possible," said Rodney Gillespie, Head of Oncology, Novartis US. "By sharing key insights with Viz.ai, we will develop AI-powered solutions to quickly help reach patients who could benefit from guideline-based targeted treatments for prostate and breast cancer, helping significantly expedite their care.'
'Too often, patients with cancer are identified late or fall through the cracks of an increasingly complex care system,' said Ethan M. Basch, MD, Chief of Oncology and Cancer Hospital Physician-in-Chief at UNC. 'AI-powered tools bring the potential to optimize how we detect, triage, and treat cancer—by delivering the right care, to the right patient, at the right time.'
With this collaboration and expansion into oncology, Viz.ai is building on its commitment to create a connected, intelligent healthcare AI layer that delivers better care for every patient, everywhere. Learn more about Viz Oncology by visiting viz.ai/pilot-programs.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.
References
Goebell PJ, Raina R, Chen SL, et al. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol. 2024;20(11):903-918. doi:10.2217/fon-2023-0814
Reynolds S. Many men with metastatic prostate cancer are not getting the recommended treatments, study finds. Cancer Currents Blog. February 18, 2025. Accessed April 21, 2025.
American Cancer Society. How common is breast cancer? American Cancer Society. Accessed April 21, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
UMC Reports Sales for June 2025
TAIPEI, Taiwan--(BUSINESS WIRE)--United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) ('UMC'), today reported unaudited net sales for the month of June 2025. Additional information about UMC is available on the web at
Business Wire
3 hours ago
- Business Wire
Circus SE Gets Awarded International Red Dot Award 'Best of Best' for Outstanding Industrial Design
MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global technology leader in AI software and robotics for the food service industry, has been awarded the prestigious international Red Dot Award for outstanding industrial design in the 'Best of the Best' category – the highest recognition in the annual Red Dot Awards. As one of the most respected global design awards, the Red Dot Award honors groundbreaking innovation across industries. With this rare distinction, Circus joins the ranks of Google, Ferrari, and Apple – whose MacBook Pro and AirPods Pro have previously earned the same honor. The CA-1 was honored in the 'Ready for Market' category which is eligible only to products that are market-ready. This category recognizes innovations that have completed the design journey and are poised for commercial deployment at scale. With serial production underway and commercial deployment beginning this fall, Circus SE's CA-1 Series 4 perfectly meets the award's criteria. Following the upcoming ceremony in October, the iconic CA-1 design will be featured in the Red Dot Winner Exhibition at the Red Dot Design Museum in Singapore, where it will be showcased to an international audience of innovators, designers, and technologists. 'This award is a powerful validation of the vision and discipline that went into the CA-1,' said Nikolas Bullwinkel, CEO and Founder of Circus SE. 'We always wanted to build a system that people trust, understand, and enjoy interacting with – something truly designed for everyday life.' The design of the CA-1 was developed in collaboration with renowned German industrial designer Mario Selic, known for his work in advanced robotics and consumer innovation with companies such as KUKA, Siemens, and Bosch and was subsequently refined and engineered for serial production by Circus' in-house teams. 'From the early sketches, the ambition was to create something radically functional yet architecturally clear – a robotic system that integrates seamlessly into human spaces,' said Selic. 'We were inspired by Edward Hopper's Nighthawks, the Airstream trailer, and Bauhaus principles – clean geometry, minimalism, and design that disappears into its surroundings while elevating them.' 'CA-1 began with a strong conceptual foundation, and throughout the design maturation, we remained committed to preserving the original design intent. We wanted to develop an autonomous product that feels effortless – for the operator, the environment, and the customer,' added Gustavo Kemmerich, Head of Mechanical Engineering and Industrial Design at Circus SE, who was instrumental over the years in bringing the CA-1 to serial manufacturing. This recognition cements Circus SE's role as a pioneer at the intersection of robotics, design, and everyday human experience – redefining how machines live, work, and serve among us. About Circus SE Circus SE (XETRA: CA1) is a global AI and robotics company developing autonomous systems for food supply in both civilian and defense sectors. Its flagship robot, the patented CA-1, is the world's first fully autonomous food production robot, now in serial production. Powered by proprietary embodied AI, Circus delivers industrial-scale, high-reliability meal output with minimal human input. Headquartered in Munich, the company is building the global infrastructure for autonomous food supply – on a mission to fuel humanity. About Red Dot The Red Dot Design Award is one of the world's most prestigious honors for outstanding design. Each year, an international jury recognizes exceptional achievements across Product Design, Brands & Communication Design, and Design Concept. With submissions from over 60 countries, Red Dot is regarded as a global benchmark for innovation, design excellence, and business differentiation. Its highest honor – 'Best of the Best' – is internationally recognized and has been awarded to groundbreaking designs and products from companies such as Apple, Google, and Ferrari. With its museum in Singapore and global visibility, the Red Dot Design Award continues to shape the role of design in both technological and societal transformation.
Business Wire
3 hours ago
- Business Wire
Best's Market Segment Report: AM Best Maintains Negative Outlook
AMSTERDAM--(BUSINESS WIRE)-- AM Best has maintained its negative outlook on France's non-life insurance segment. In its new Best's Market Segment Report, 'Market Segment Outlook: France Non-Life Insurance', AM Best states that non-life insurance growth prospects are expected to remain limited over the next months, tied to modest GDP growth expectations. The report also notes that the increase in frequency and severity of natural catastrophe events is expected to continue to put pressure on France's non-life insurers, despite the existence of the state-backed natural catastrophe scheme, Caisse Centrale de Réassurance (CCR). While a surcharge to existing premiums has been added since the start of 2025 to release some of the short-term pressure on CCR, AM Best believes that it will not be sufficient over the medium term amid changing climate trends and that further measures will have to be discussed to ensure the scheme's sustainability. To access a complimentary copy of this special report, please visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
